Print | Email Page

XOMA establishes global patent portfolio for IL-1 beta antibodies

Jones Day represents XOMA Corporation for their global patent portfolio for antibodies to IL-1 beta, including gevokizumab, for the treatment of a variety of inflammatory diseases and disorders.

For additional information about this matter, please contact: Janet M. McNicholas Ph.D.

Client(s): XOMA Corporation
Office(s): Silicon Valley